Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Medications development: successes and challenges.

Vocci F, Ling W.

Pharmacol Ther. 2005 Oct;108(1):94-108. Review.

PMID:
16083966
2.

Medication development for addictive disorders: the state of the science.

Vocci FJ, Acri J, Elkashef A.

Am J Psychiatry. 2005 Aug;162(8):1432-40. Review.

PMID:
16055764
3.

Pharmacotherapy and other treatments for cocaine abuse and dependence.

Vocci FJ, Elkashef A.

Curr Opin Psychiatry. 2005 May;18(3):265-70.

PMID:
16639150
4.
5.

Addiction pharmacotherapy 2000: new options, new challenges.

Rawson RA, McCann MJ, Hasson AJ, Ling W.

J Psychoactive Drugs. 2000 Oct-Dec;32(4):371-8. Review.

PMID:
11210198
6.

Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.

McCann DJ.

Clin Pharmacol Ther. 2008 Apr;83(4):627-30. doi: 10.1038/sj.clpt.6100503. Epub 2008 Jan 23. Review.

PMID:
18212797
7.

Pharmacotherapy of addictions.

Kreek MJ, LaForge KS, Butelman E.

Nat Rev Drug Discov. 2002 Sep;1(9):710-26. Review. Erratum in: Nat Rev Drug Discov 2002 Nov;1(11):920.

PMID:
12209151
8.
9.

Buprenorphine for the treatment of opioid dependence.

Boothby LA, Doering PL.

Am J Health Syst Pharm. 2007 Feb 1;64(3):266-72. Review.

PMID:
17244875
10.

Opioid dependence: rationale for and efficacy of existing and new treatments.

Fiellin DA, Friedland GH, Gourevitch MN.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S173-7. Review.

PMID:
17109303
11.

Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.

Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J.

Arch Gen Psychiatry. 2005 Oct;62(10):1157-64.

PMID:
16203961
12.

New developments in the pharmacotherapy of cocaine abuse.

Preti A.

Addict Biol. 2007 Jun;12(2):133-51. Review.

PMID:
17508985
13.

Pharmacologic treatments for drug and alcohol dependence.

Kranzler HR, Amin H, Modesto-Lowe V, Oncken C.

Psychiatr Clin North Am. 1999 Jun;22(2):401-23. Review.

PMID:
10385941
14.

Involving the pharmaceutical and biotech communities in medication development for substance abuse.

Gorodetzky CW, Grudzinskas C.

Pharmacol Ther. 2005 Oct;108(1):109-18. Review.

PMID:
16038981
15.

Buprenorphine for office-based treatment of patients with opioid addiction.

Manlandro JJ Jr.

J Am Osteopath Assoc. 2005 Jun;105(6 Suppl 3):S8-13. Review.

PMID:
16118361
16.

Pharmacotherapy for pregnant women with addictions.

Rayburn WF, Bogenschutz MP.

Am J Obstet Gynecol. 2004 Dec;191(6):1885-97. Review.

PMID:
15592269
17.

Using buprenorphine for outpatient opioid detoxification.

Manlandro JJ Jr.

J Am Osteopath Assoc. 2007 Sep;107(9 Suppl 5):ES11-6. Review.

PMID:
17908825
18.

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Gerra G, Fantoma A, Zaimovic A.

J Psychopharmacol. 2006 Nov;20(6):806-14. Epub 2006 Jan 9.

PMID:
16401652
19.

Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.

Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, Scheuer N, Mattick RP.

Med J Aust. 2009 Aug 3;191(3):161-5.

PMID:
19645647
20.

Overview: medications development for the treatment of drug abuse.

Vocci F, Chiang CN, Cummings L, Hawks R.

NIDA Res Monogr. 1995;149:4-15.

PMID:
8775832

Supplemental Content

Support Center